SwitzerlandSwitzerland

Genentech starts study with Swiss antibody

14.12.2011

Geneva – There's is life in Swiss biotechnology beyond big pharma. Genentech has launched a First-in-Human study with anti-IL-17, an antibody made by the Swiss biotechnology company NovImmune. The fully human monoclonal antibody, which may be suitable to treat inflammatory and autoimmune diseases, is designed to specifically and selectively bind to the human IL-17 family of cytokines NovImmune has developed its own technology to make monoclonal antibodies, or bioengineered molecules that mimic the action of the body’s own response to infections. Anti-IL-17 was licensed to Genentech in July 2010. The initiation of the Phase I clinical trial triggers a milestone payment from Genentech of an undisclosed amount. "This is the fifth NovImmune therapeutic antibody to enter clinical development", said Novimmune's CEO Jack Barbut. Two compounds are already in Phase II.

SwitzerlandSwitzerland

21.02.2012

Basel/Berkeley – Europe enters into the age of personalised medicine. The European Commission has approved the melanoma drug Zelboraf. While the compound was developed by US-based Plexxikon Inc., owned by Daiichi Sankyo Group,...

SwitzerlandSwitzerland

26.01.2012

Basel – The rumours started just before Christmas. Roche wants Illumina. Just how dearly, has just become clear. The Swiss drugmaker made a $5.7b hostile bid for Illumina, the current market leader in Next-Generation sequencing....

SwitzerlandSwitzerland

23.01.2012

Basel – Good and bad news for Swiss drugmaker Novartis. First a look on the bright side: Signifor, for the treatment of Cushing's disease, is on its final stretch to approval. The Committee for Medicinal Products for Human Use...

SwitzerlandSwitzerland

19.12.2011

Basel - It is a further push for Roche's ambitions in medicine concerning the treatment of skin cancer: The European Committee for Medicinal Products for Human Use (CHMP) has recommended that the drug Zelboraf and its companion...

SwitzerlandSwitzerland

17.12.2011

Allschwil – Europe’s largest stand-alone biotech company Actelion Ltd. is receiving an injection of fresh capital. Under the guidance of the two biggest Swiss banks – UBS and Credit Suisse – the Swiss company will be issued a...

SwitzerlandSwitzerland

14.12.2011

Stans – Due to the current financial market conditions and the lack of significant progress with currently available options, Swiss drug developer Mondobiotech says it will be implementing restructuring measures. Together with...

SwitzerlandSwitzerland

22.11.2011

Basel – The FDA has withdrawn the accelerated approval for Roche's Avastin (bevacizumab) to treat metastasising breast cancer. The US regulatory authority had originally granted accelerated approval for Avastin's use in treating...

SwitzerlandSwitzerland

16.11.2011

Basel/Hervel – It may be the end of Novartis' lucky streak in osteoporosis. While the once a year osteoporosis injection Aclasta (a bisphosphonate) sells well, the Swiss pharma company had to break disastrous news from a...

SwitzerlandSwitzerland

11.11.2011

Ghent/Geneva - Ablynx rides the biotech rollercoaster. Only days after US-pharma company Pfizer pulled out of a rheumatoid arthritis pact, the Belgian bipharmaceutical outfit expanded its relationship with Merck Serono. Ablynx...

Displaying results 11 to 20 out of 276

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-switzerland/browse/1/article/genentech-starts-study-with-swiss-antibody.html

Events

All Events

Stock list

All quotes

TOP

  • LONZA107.50 CHF3.46%
  • MORPHOSYS72.46 EUR2.96%
  • SANTHERA95.00 CHF2.48%

FLOP

  • 4SC1.18 EUR-4.07%
  • CYTOS0.25 CHF-3.85%
  • BIOFRONTERA2.32 EUR-3.33%

TOP

  • SANTHERA95.00 CHF58.6%
  • EPIGENOMICS3.72 EUR16.2%
  • BB BIOTECH147.00 EUR13.6%

FLOP

  • BIOFRONTERA2.32 EUR-13.4%
  • WILEX2.36 EUR-12.6%
  • MEDIGENE4.30 EUR-11.3%

TOP

  • SANTHERA95.00 CHF3715.3%
  • CO.DON2.46 EUR207.5%
  • PAION2.41 EUR153.7%

FLOP

  • CYTOS0.25 CHF-93.7%
  • THERAMETRICS0.08 CHF-42.9%
  • MERCK KGAA66.45 EUR-42.3%

No liability assumed, Date: 02.09.2014


Current issue

All issues

Product of the week

Products